Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06541002 · ClinicalTrials.gov registry record · NA

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

A NA study of Sexual Dysfunction and Stem Cell Transplant Complications, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
3
Study locations

NCT06541002: Recruiting NA study of Sexual Dysfunction and Stem Cell Transplant Complications, sponsored by Massachusetts General Hospital.

NCT06541002 is a NA study of Sexual Dysfunction and Stem Cell Transplant Complications that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 300 participants, below the 953-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06541002, a NA study of Sexual Dysfunction and Stem Cell Transplant Complications, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
3
Study locations

Study Summary

This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.

Primary Outcome

To compare patient global satisfaction with sex scores at week 8 after enrollment between those receiving SHIFT versus enhanced usual care as measured by the PROMIS global satisfaction with sex domain from the PROMIS Scale v2.0 Satisfaction with Sex Life. Higher scores indicate higher satisfaction with sex life, and lower scores indicate less satisfaction with sex life.

Interventions

  • BEHAVIORAL SHIFT Intervention Group
  • BEHAVIORAL Enhanced Usual Care Group

Study Locations (3)

Florida

  • University of Miami - Coral Gables

Massachusetts

  • Massachusetts General Hospital (MGH) - Boston

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-01-27
Est. Completion 2030-04-30
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06541002 shows while recruiting

NCT06541002 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 953-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (69% lower).

The record links to 3 conditions, with Sexual Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which SHIFT Intervention Group is the first listed.

NCT06541002 reports a single indexed study location in Florida, Massachusetts, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06541002 about?

NCT06541002 is a clinical study titled "A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors". This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.

What is the current status of trial NCT06541002?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-01-27. Estimated completion is 2030-04-30.

What conditions does trial NCT06541002 study?

This clinical trial studies the following conditions: Sexual Dysfunction, Stem Cell Transplant Complications, Bone Marrow Transplant Complications.

What interventions are being tested in trial NCT06541002?

The interventions under investigation include: SHIFT Intervention Group (BEHAVIORAL), Enhanced Usual Care Group (BEHAVIORAL).

Who is sponsoring clinical trial NCT06541002?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06541002 being conducted?

This trial has 3 study locations across Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sexual Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06541002's enrollment target sits among peer trials

300 4th of 20 higher than 17 of 20 other Sexual Dysfunction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sexual Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06541002, the US trial registry maintained by the National Library of Medicine. NCT06541002 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.